AR091457A1 - Tratamiento de celulas pluripotentes - Google Patents

Tratamiento de celulas pluripotentes

Info

Publication number
AR091457A1
AR091457A1 ARP130102110A AR091457A1 AR 091457 A1 AR091457 A1 AR 091457A1 AR P130102110 A ARP130102110 A AR P130102110A AR 091457 A1 AR091457 A1 AR 091457A1
Authority
AR
Argentina
Prior art keywords
pluripotent cells
gsk
inhibitor
tra1
ssea
Prior art date
Application number
Other languages
English (en)
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AR091457A1 publication Critical patent/AR091457A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Reivindicación 1: Un método para expandir y diferenciar células pluripotentes; el método comprende las etapas de: a) cultivar células pluripotentes y b) tratar las células pluripotentes con un inhibidor de la actividad enzimática de GSK-3B. Reivindicación 4: El método de conformidad con la reivindicación 3, en donde las células que expresan marcadores de pluripotencia expresan por lo menos uno de los siguientes marcadores de pluripotencia seleccionados del grupo que consiste en: ABCG2, cripto, FoxD3, Connexin43, Connexin45, Oct4, SOX-2, Nanog, hTERT, UTF-1, ZFP42, SSEA-3, SSEA-4, Tra1-60 y Tra1-81. Reivindicación 7: El método de conformidad con la reivindicación 1, en donde las células pluripotentes se tratan con el inhibidor de la actividad enzimática de GSK-3B por aproximadamente 12 a aproximadamente 48 horas. Reivindicación 12: El método de conformidad con la reivindicación 1, en donde el inhibidor de la actividad enzimática de GSK-3B es un compuesto de la fórmula (1).
ARP130102110 2012-06-14 2013-06-14 Tratamiento de celulas pluripotentes AR091457A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261741776P 2012-06-14 2012-06-14

Publications (1)

Publication Number Publication Date
AR091457A1 true AR091457A1 (es) 2015-02-04

Family

ID=49756254

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102110 AR091457A1 (es) 2012-06-14 2013-06-14 Tratamiento de celulas pluripotentes

Country Status (14)

Country Link
US (1) US20130337564A1 (es)
EP (1) EP2861723A4 (es)
JP (1) JP2015519085A (es)
KR (1) KR20150030709A (es)
CN (1) CN104603262A (es)
AR (1) AR091457A1 (es)
BR (1) BR112014031424A2 (es)
CA (1) CA2876671A1 (es)
MX (1) MX2014015419A (es)
PH (1) PH12014502748A1 (es)
RU (1) RU2015100900A (es)
SG (1) SG11201408150UA (es)
WO (1) WO2013192005A2 (es)
ZA (1) ZA201500224B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
MX2015017103A (es) 2013-06-11 2016-11-07 Harvard College Celulas beta derivadas de células madre ( sc-beta ) y composiciones y métodos para generarlas.
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2016100898A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof
EP3234110B1 (en) 2014-12-18 2024-02-28 President and Fellows of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED ß CELLS AND USES THEREOF
WO2016100930A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Methods for generating stem cell-derived b cells and methods of use thereof
ES2968146T3 (es) * 2016-08-18 2024-05-08 Nat Univ Singapore Derivados de azol sustituidos para la generación, proliferación y diferenciación de células madre y progenitoras hematopoyéticas
WO2018090084A1 (en) * 2016-11-16 2018-05-24 Cynata Therapeutics Limited Pluripotent stem cell assay
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
IL313115A (en) 2017-05-05 2024-07-01 Centre For Probe Dev And Commercialization R1–IGF monoclonal antibodies and their use
JP2020518673A (ja) 2017-05-05 2020-06-25 フュージョン・ファーマシューティカルズ・インコーポレイテッド 二官能性キレートの薬物動態増強及びその使用
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
KR101966523B1 (ko) * 2017-05-29 2019-04-05 차의과학대학교 산학협력단 오가노이드 배양을 위한 조성물 및 방법
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
IL305391B2 (en) 2017-11-15 2024-09-01 Vertex Pharma Preparations for the production of islet cells and methods of use
EP3801638A1 (en) * 2018-06-08 2021-04-14 Novartis AG Cell-based assay for measuring drug product potency
EP3833365A4 (en) 2018-08-10 2022-05-11 Vertex Pharmaceuticals Incorporated ISLE DIFFERENTIATION DERIVED FROM STEM CELLS
US10724052B2 (en) 2018-09-07 2020-07-28 Crispr Therapeutics Ag Universal donor cells
CA3150235A1 (en) 2019-09-05 2021-03-11 Alireza Rezania UNIVERSAL DONOR CELLS
KR20220058579A (ko) 2019-09-05 2022-05-09 크리스퍼 테라퓨틱스 아게 보편적 공여자 세포
AU2021414617A1 (en) 2020-12-31 2023-08-10 Crispr Therapeutics Ag Universal donor cells
WO2024124463A1 (zh) * 2022-12-15 2024-06-20 武汉睿健医药科技有限公司 一种吡咯并吡啶衍生物及其药物组合物与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060030042A1 (en) * 2003-12-19 2006-02-09 Ali Brivanlou Maintenance of embryonic stem cells by the GSK-3 inhibitor 6-bromoindirubin-3'-oxime
GB2444686B (en) * 2005-09-12 2010-08-25 Es Cell Int Pte Ltd Differentiation of pluripotent stem cells using p38 MAPK inhibitors or prostaglandins
US8741643B2 (en) * 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
US8623648B2 (en) * 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US7939322B2 (en) * 2008-04-24 2011-05-10 Centocor Ortho Biotech Inc. Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm

Also Published As

Publication number Publication date
US20130337564A1 (en) 2013-12-19
SG11201408150UA (en) 2015-01-29
RU2015100900A (ru) 2016-08-10
JP2015519085A (ja) 2015-07-09
BR112014031424A2 (pt) 2017-06-27
EP2861723A4 (en) 2016-01-20
CN104603262A (zh) 2015-05-06
WO2013192005A3 (en) 2014-03-13
PH12014502748A1 (en) 2015-02-02
ZA201500224B (en) 2017-09-27
EP2861723A2 (en) 2015-04-22
CA2876671A1 (en) 2013-12-27
WO2013192005A2 (en) 2013-12-27
KR20150030709A (ko) 2015-03-20
MX2014015419A (es) 2015-07-14

Similar Documents

Publication Publication Date Title
AR091457A1 (es) Tratamiento de celulas pluripotentes
AU2018260810A1 (en) Defined media for expansion and maintenance of pluripotent stem cells
RU2010147817A (ru) Плюрипотентные клетки
PH12014502686A1 (en) Differentiation of human embryonic stem cells into pancreatic endoderm
EP4382171A3 (en) Method for rejuvenating cells
PH12015501450A1 (en) Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators
MX2021005715A (es) Derivacion sin alimentadores de celulas madre pluripotentes inducidas humanas con arn mensajero sintetico.
EP2580320A4 (en) REPROGRAMMING CELLS TO CONFERUE THEM WITH A NEW DESTINY
NZ706806A (en) Compositions and methods for autologous germline mitochondrial energy transfer
CA2909230C (en) Method for inducing alveolar epithelial progenitor cells
WO2016168890A8 (en) Generation of muscle-lineage cells from stem cells
NZ627835A (en) Feeder-free method for culture of bovine and porcine spermatogonial stem cells
PH12014501426A1 (en) Induced pluripotent stem cells from human umbilical cord tissue-derived cells
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
SG11201505965TA (en) Culture method for stable undifferentiated proliferation of pluripotent stem cells
IL275568A (en) Efficient production of stable multipotent prime embryonic stem cells
MX2019005476A (es) Ensayo de celulas madre pluripotentes.
EP2295538A4 (en) METHOD FOR PRODUCING PLURIPOTENT STEM CELL
AU2012256014A8 (en) Use of Zscan4 and Zscan4-dependent genes for direct reprogramming of somatic cells
EP3892719A4 (en) UNDIFFERENTIATED STATE-MAINTAINING CULTURE MEDIUM FOR PLURIPOTENTIC STEM CELLS
BR112018070293A2 (pt) diferenciação de células-tronco pluripotentes em células do endoderma intestinal do intestino médio
PL3436568T3 (pl) Podłoże hodowlane do pluripotencjalnych komórek macierzystych
SG11201903254PA (en) Undifferentiated stem cell-removing agent, and method for removing undifferentiated stem cells
BR112015015466A2 (pt) método para cultivar células-tronco pluripotentes
MX2016014008A (es) Metodo para diferenciacion de celulas madre pluripotentes en cardiomiocitos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure